AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DIACEUTICS PLC

Director's Dealing Mar 31, 2022

7596_dirs_2022-03-31_3904fda8-62a4-4ab9-b0b2-204dbc50edd1.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 8475G

Diaceutics PLC

31 March 2022

31 March 2022

Diaceutics PLC

("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company has been notified that on 28 March 2022, Yorkshire Building Society have purchased ordinary shares ("Shares") on behalf of Stefan Macdonald (PDMR), in respect of his purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for  employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde [email protected]
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Stefan Macdonald
2 Reason for notification
a. Position/Status Chief Growth Officer and PDMR
b. Initial notification/

Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary shares of £0.002 each

ISIN:  GB00BJQTGV64
b. Nature of the transaction Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
108.00 p 139
Matched share award:
Price(s) Volume(s)
108.00 p 278
e. Date of the transaction Share purchase and Matched Share award: 28 March 2022
f. Place of the transaction Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKDBNABKDPNN

Talk to a Data Expert

Have a question? We'll get back to you promptly.